EXPAREL is a long-lasting non-opioid option proven to manage postsurgical pain

EXPAREL can be administered via infiltration, interscalene brachial plexus nerve block, and fascial plane blocks to provide long-lasting non-opioid pain control

More than 14 million patients have received non-opioid EXPAREL since 2012. EXPAREL works locally at the surgical site and uses the proprietary multivesicular liposome (pMVL) technology, which encapsulates bupivacaine in a suspension of multivesicular liposomes. After injection, bupivacaine is released over time.^1,2

The pMVL technology and versatility of administration enables infiltration into the surgical site to produce local analgesia, in the fascial plane to produce regional analgesia as a regional field block or as an interscalene brachial plexus nerve block. EXPAREL may be used across surgical procedures and has demonstrated improved clinical and economic outcomes.

Infiltration

Broad indication across surgical procedures to provide regional analgesia

Nerve Blocks

Use EXPAREL to provide nerve blocks in procedures such as total shoulder arthropplasty, rotator cuff repairs, knee or foot and ankle surgeries

EXPAREL IN INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK

EXPAREL in Adductor Canal Block

EXPAREL in Sciatic Nerve Block in the Popliteal Fossa

Field blocks (ie, TAP & PECS)

Use EXPAREL to provide effective regional field or interfascial plane blocks in a range of procedures

EXPAREL IN ABDOMINAL FIELD BLOCKS

EXPAREL IN PECS BLOCKS

TAP, transversus abdominis plane.

The broad indication of EXPAREL affords versatility of administration

Administer as surgical site infiltration to produce local analgesia, as a field block to produce regional analgesia, or in adults, as an interscalene brachial plexus nerve block.

dosing video thumb

Connect with us

Important Notice

This site is intended to provide medical and product information to health care professionals in the United States.

To report an adverse event, email drugsafety@pacira.com or call 1-855-793-9727.

For medical inquiries related to EXPAREL, submit a request to Medical Information or call 1-855-793-9727.

These are not all of the potential important safety considerations for EXPAREL; please see the full Prescribing Information.

References

Malik O, Kaye AD, Kaye A, Belani K, Urman RD. Emerging roles of liposomal bupivacaine in anesthesia practice. J Anaesthesiol Clin Pharmacol. 2017;33(2):151-156.
Portillo J, Kamar N, Melibary S, Quevedo E, Bergese S. Safety of liposome extended-release bupivacaine for postoperative pain control. Front Pharmacol. 2014;5:90.

Indication

EXPAREL^® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.
Adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via nerve block were nausea, pyrexia, headache, and constipation.
Adverse reactions with an incidence greater than or equal to 10% following EXPAREL administration via infiltration in pediatric patients six to less than 17 years of age were nausea, vomiting, constipation, hypotension, anemia, muscle twitching, vision blurred, pruritus, and tachycardia.
Do not admix lidocaine or other non-bupivacaine local anesthetics with EXPAREL. EXPAREL may be administered at least 20 minutes or more following local administration of lidocaine.
EXPAREL is not recommended to be used in the following patient populations: patients <6 years old for infiltration, patients younger than 18 years old for nerve blocks, and/or pregnant patients.
Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.
EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and adductor canal block, or intravascular or intra-articular use.
The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.
Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability, which may lead to dysrhythmias, sometimes leading to death.
Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.
Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.
Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Please refer to full Prescribing Information.

EXPAREL^® (bupivacaine liposome injectable suspension) is indicated to produce postsurgical local analgesia via infiltration in patients aged 6 years and older and regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa, and an adductor canal block. Safety and efficacy have not been established in other nerve blocks.

Important Safety Information